Sanofi shares lose momentum but remain up 21% over one month
The pharmaceutical company loses momentum after a series of recent highs, in a Paris market trending downward. The stock remains well above its moving averages, after a month of strong recovery.
A pullback that leaves the stock well above its moving averages
The Sanofi share falls 1.31% to €87.16 in early afternoon trading, while the CAC 40 drops 0.88% to 8,278 points.
The decline follows the rise of recent weeks: the stock still gains 21.16% over one month, and the highest of 250 sessions was reached on Monday. This movement keeps the price 7.13% above the MM20 and 13.24% above the MM200.
The RSI at 75 remains in overbought territory, consistent with the recent rise, and the resistance level at €88.32 is very close to the price of the day.
In the CAC 40 ranking, the stock sits in the lower part of the index, without being among the largest decliners. The sector is not moving uniformly: Eurofins Scientific falls 1.37% and Nanobiotix 4.71% this Tuesday.
A market context dominated by the AI correction and French debt
The session takes place against a backdrop of broad decline: the Nasdaq lost 2.49% and the S&P 500 1.92% on Monday on Wall Street, while the Nikkei fell 1.34% and the Hang Seng 1.03% this Tuesday.
According to the day's news reports, the decline in artificial intelligence-related stocks dominates these sessions. The VIX gains 17.88% to 22.75. In France, the 10-year OAT stands at 4.91% on November 17, with a spread of 1.56 points over the Bund.
On valuation, according to the consensus of the analysts surveyed, Sanofi trades at about 9.8 times earnings for the current fiscal year. The company's latest published financial release dates back to October 30: the laboratory had then raised its 2026 targets after a third quarter up 14.3%.
The resistance level at €88.32, less than 1.5% from the price, is the nearest technical level.